CYRX — Cryoport, Inc.

Summary of Cryoport's Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Full Year Revenue: Cryoport reported $176.2 million in revenue from continuing operations for FY 2025, exceeding guidance.
• Q4 Revenue Growth: Achieved double-digit revenue growth, with commercial cell and gene therapy revenue increasing 29% year-over-year to $33.4 million.
• Clinical Trial Revenue: Grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials.
• Gross Margin: Improved to 47%, reflecting successful cost reduction initiatives.
• Adjusted EBITDA: Showed a $12 million year-over-year improvement, with expectations of achieving positive adjusted EBITDA in H2 2026.

2. Strategic Updates and Business Highlights:

• Partnerships: Established a strategic partnership with DHL, which included the sale of CRYOPDP, expected to enhance Cryoport's market position in APAC and EMEA.
• Service Expansion: Expanded services through collaborations with Cardinal Health and Parexel, enhancing supply chain solutions for cell and gene therapies.
• Product Innovations: MVE Biological Solutions launched integrated condition monitoring solutions and the Fusion 800 Series cryogenic freezer, aimed at expanding market opportunities.
• Operational Investments: Continued investments in global supply chain centers in Paris and California to support growth.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Projected revenue between $190 million and $194 million, indicating a growth rate of approximately 9% at the midpoint.
• Clinical Trials Pipeline: Anticipating 13 BLA/MAA application filings and 9 new therapy approvals in 2026, with a strong pipeline of clinical trials (86 in Phase III, 361 in Phase II).

4. Challenges and Points of Concern:

• Market Volatility: Acknowledged potential macroeconomic headwinds that could impact growth, although no specific risks were identified.
• MVE Segment Growth: MVE revenue growth was 7% for the year, with Q4 growth slowing to 2%. Future growth is expected to be moderate, with potential for high single-digit growth depending on demand recovery.
• Integration with DHL: The integration process with DHL is expected to take time, which may delay the realization of benefits from the partnership.

5. Notable Q&A Insights:

• Funding Lag: Typically, there is a 6-month lag between biopharma funding and increased customer orders.
• Operational Milestones for EBITDA: Positive adjusted EBITDA is expected due to operational efficiencies and growth initiatives rather than cost-cutting alone.
• Commercial Therapy Growth: The company emphasized that commercial cell and gene therapy will be the primary growth driver, outpacing other segments.
• Regulatory Environment: Changes in FDA requirements, such as moving towards a single pivotal trial, could streamline approvals and enhance revenue potential, particularly for community care settings.

Overall, Cryoport demonstrated strong financial performance in 2025, with a positive outlook for 2026 driven by strategic partnerships and a robust pipeline in cell and gene therapy, despite acknowledging potential market challenges and the need for careful integration with DHL.